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ABSTRACT

CHARACTERIZATION OF THE ROLE OF SOX9 IN
CARTILAGE-SPECIFIC GENE REGULATION

Mary Ann Genzer
Department of Microbiology and Molecular Biology
Master of Science

Although advances have been made toward understanding the complex
mechanisms that regulate the process of DNA transcription, the specific mechanisms of
activation for many individual genes remain unknown. In this study, we focus on the role
the transcription factor SOX9 plays in activating cartilage-specific genes, specifically
Col9a1 and Cartilage Link Protein (CRTL1). Previously, enhancers of these genes
containing single SOX9 binding sites were shown to be activated through SOX9 binding.
However, the hypothesis was made that in cartilage-specific genes dimeric SOX9, as
opposed to monomeric SOX9, is necessary for activation. We identified a putative
binding site adjacent to each of the known single SOX9 binding sites in the Col9a1 D and
E enhancers and in the CRTL1 enhancer.

Electrophoretic Mobility Shift Assays

(EMSAs) were performed to determine whether SOX9 bound to these putative sites.

Transient transfections were then performed using wild-type and mutant enhancerreporter plasmids to determine whether these putative SOX9 binding sites were important
for activation in vivo. Although dimeric SOX9 bound to each of the enhancers in vitro,
several different effects were seen in vivo. In the presence of the wild-type Col9a1 D
enhancer, no activation was seen. However, when the enhancer was extended to include
an additional pair of newly found SOX9 binding sites, expression was increased 10-fold.
When any of the four SOX9 binding sites within this enhancer were mutated, expression
was completely eliminated, suggesting that interdependent dimers or a tetramer of SOX9
is necessary for the activation of transcription. The weaker Col9a1 enhancer E was found
to increase gene expression minimally through binding of either dimeric or monomeric
SOX9. However, dimeric SOX9 was required for the activation of gene expression by the
CTRL1 enhancer. Through this study we validate the importance of not just monomeric
but of dimeric and possibly tetremeric SOX9 as an activator of cartilage-specific gene
expression.
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INTRODUCTION

Gene Expression
Great advances have been made toward understanding the complex mechanisms
that regulate the process of DNA transcription. However, the specific mechanisms of
activation for many individual genes are unknown. The following research focuses on the
mechanism of activation pertaining to a small subset of cartilage genes and suggests a
new model for gene activation. Before addressing the current research, three main parts
of general transcriptional activation are reviewed including DNA unwinding, formation
of transcriptional initiation complex, and the role of transcription factors.
In the first step necessary to begin transcription, eukaryotic DNA is released from
its inactive chromatin structure, where it is tightly coiled around protein, to a more open
state thus allowing regulatory DNA binding proteins access to the DNA. Genes that are
about to be transcribed must undergo these loosening structural changes, which are
usually brought about by chromatin remodeling, histone modification, or a combination
of these methods (9). Chromatin remodeling factors complex with DNA, hydrolyze ATP,
and use the released energy to disrupt the packaging structure. Histone modification
reduces the positive charge on histones lessening the binding force with DNA.
Once the eukaryotic DNA is loosened from the chromatin structure, several
proteins essential for transcription, including RNA polymerase II (Pol II), are uninhibited
from binding to the core promoter. The core promoter is a DNA region where the
complex of general transcription factors, co-activators and Pol II are positioned in order
to initiate transcription at the start site (4). In most eukaryotes this begins with the protein
TFIID binding to the TATA box sequence within the core promoter which results in
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recruitment of remaining general transcription factors and the initiation of transcription
(4). Participating in the recruitment of these key proteins, which initiate transcription, are
gene or tissue specific transcription factors that also play a part in initiation of
transcription.
Transcription factors, which act as either activators or repressors, bind to DNA
and interact with the promoter to further regulate levels of gene expression. Specifically,
activators bind to enhancers and increase gene expression. Enhancer elements can be in
close proximity or far away from the promoter, located upstream, downstream, or within
a transcriptional unit. When the DNA is in the loosened state needed for transcription,
these enhancer regions become available for activators to bind. After recognizing specific
DNA structures or sequences, these activators or transcription factors bind to enhancers
and induce conformational changes. The conformational changes facilitate interactions
between transcription factors and other co-activators or the Pol II complex thus resulting
in regulated transcription. Our current study focuses on the interaction of the transcription
factor SOX9 with enhancers and on the gene regulation that results.
SOX Transcription Factors
The transcription factor SOX9 belongs to the HMG box superfamily. The proteins
within this superfamily contain a high mobility group (HMG) domain which enables
them to bind DNA. A subgroup of the HMG superfamily is the SRY-type HMG box (or
SOX) protein family named after the testis-determining factor, SRY. Each SOX protein
contains an HMG domain composed of three α-helices forming a twisted L-shape
maintained by a hydrophobic core. The SOX protein HMG domain binds the DNA upon
specific sequence recognition.

The consensus sequence for SOX binding has been
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specified as the heptameric sequence (A/T)(A/T)CAA(A/T)G (14). Upon recognition of
this sequence, SOX proteins bind in the minor groove and the DNA undergoes a
conformational change resulting in a 70-85° bend and unwinding (14).
Along with including an HMG domain, the proteins belonging to group E of the
SOX gene family (10) (SOX8, SOX9 and SOX10) contain at least one transactivation
domain as well as a dimerization domain (14).When the PQS transactivation domain of
SOX8, SOX9, and SOX10 is removed the proteins are no longer able to activate
transcription (6). SOX9 contains an additional transactivation domain, PQA, which is not
present in SOX8 or SOX10. The dimerization domains found in these three proteins
allow for cooperative binding between proteins, making possible the formation of DNAdependent heterodimers and homodimers (1). Dimerization made possible by the
presence of this domain has been shown to be key in the regulatory mechanisms of SOX9
in particular.
Dimerized SOX9 activates several genes that are critical for chondrogenesis. The
enhancers of these cartilage-specific genes often contain multiple SOX9 binding sites,
and these multiple sites are often paired in opposite orientation with a 3-4 base pair
separation. The paired sites allow for the DNA-dependent dimerization of SOX9. In these
enhancers, it is often seen that upon mutation of one SOX9 binding site in a pair, the
other site is rendered inactive as well. The cartilage-specific genes that are activated by
SOX9 include Col2a1, Col11a2, Col9a2, Col27A, and CD-RAP, all of which contain
multiple SOX9 binding sites.
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Background Studies
Collagens expressed in cartilage that have been shown to be regulated by SOX9
include types II, IX, XI, and XXVII. Col2a1 was the first collagen gene to be identified
as being activated by SOX9. SOX9 binds to three sites in the enhancer region to activate
transcription. If any of these sites are mutated, SOX9 is no longer capable of activating
transcription (17). Col11a2 was found to have three paired SOX9 binding regions, one of
which is intronic. Dimerization of SOX9 at each of these sites is essential for full
transcriptional activation to occur (2, 3). In Col9a2, paired SOX9 binding sites, which
bind dimerized SOX9, were found to be important in activating gene expression (1).
COL27A1 was also found to have two paired SOX9 binding sites that, when bound by
SOX9, activate transcription (7). Taken together, this work has shown that dimerized
SOX9 plays an important role in collagen gene activation.
Other work has shown SOX9 to function in the regulation of non-collagen
cartilage genes expressing proteins such as cartilage-derived retinoic acid-sensitive
protein (CD-RAP) and aggrecan. SOX9 bound to paired binding sites found in a enhancer
region for CD-RAP are necessary for full gene expression (5, 13, 15). SOX9 has also
been found to transactivate aggrecan expression in some cell lines, however, binding sites
have not been identified (11). Thus, SOX9 not only acts as a transcription factor
important for collagen gene expression but also for the expression of other essential
cartilage proteins as well.
In addition to activating cartilage-specific genes, SOX9 plays a critical role in sex
determination. Both the anti-Mullerian hormone (AMH) gene, which leads to regression
of the female reproductive tract and Steroidogenic Factor 1 (SF1) gene, which is critical
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for gonad development, are shown to be regulated by SOX9 (1). In humans, the mutation
of SOX9 results in Campomelic dysplasia (CD), a disease that is not only characterized
by skeletal abnormalities but also by XY sex reversal in about two-thirds of patients (13).
This illustrates the importance of SOX9 regulation in both cartilage gene expression and
sex determination.
It was proposed by Bernard et al. in 2003 that dimerization of SOX9 is required
for activation of genes involved in chondrogenesis but not for sex determination (1). The
missense mutation A76E in the dimerization domain of SOX9 disrupts the capability of
dimerization and thus the role of dimerized SOX9 was able to be tested. In the
experiments conducted, mutant A76E SOX9 protein was not effective in activating either
the Col11a2 or Col9a1 enhancers but the activation of SF1 enhancer was not affected,
supporting this hypothesis (1).
Three recently identified cartilage-specific gene enhancers have been shown by
others to be activated by SOX9 (8, 16). However, the role of dimerized SOX9 on these
enhancers was not considered. Col9a1 was shown to have two enhancers, D and E, each
containing a single SOX9 binding site essential for activation (16). The gene for cartilage
link protein (CRTL1), a key component of cartilage extracellular matrix, was also shown
to have an enhancer containing a single SOX9 binding site critical for activation (8). We
hypothesized that these enhancers may also be subject to regulation by dimerized SOX9
and upon sequence examination we found potential SOX9 binding sites adjacent to each
of the sites previously identified. These potential binding sites are each arranged in
opposite orientation to the primary site, and the two sites in each pair are separated by 3-4
base pairs as are all functional SOX9 binding site pairs previously identified.
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The goal of my work was to test all three of the enhancers to see if the adjacent
sites were in fact functional SOX9 binding sites and whether they played a role in the
transcriptional activity of each enhancer. We found that SOX9 dimerization was required
for full transcriptional activity of the CRTL1 enhancer but not the Col9a1 E enhancer.
Most surprisingly, we found that the Col9a1 D enhancer actually contains four SOX9
binding sites arranged in two pairs. The individual mutation of any one of the four sites
completely inactivated the enhancer, suggesting that SOX9 interacts with the enhancer
not as two separate dimers but rather as two interdependent dimers or even as a tetramer.
This is the first time SOX9 has been found to activate transcription in this manner.
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METHODS

Enhancer Synthesis and Purification
Complementary primers were designed for each enhancer region containing either
wild-type paired SOX9 binding sites or substitution mutations in either the upstream or
downstream site of each pair. These primers were designed for CRTL1 enhancer, Col9a1
enhancer D, and Col9a1 enhancer E, and mutations were designed to prevent SOX9
binding by creating a total of four mismatches with the consensus SOX9 binding
sequence at each site (Table 1). Each enhancer had a 5’ GATC overhang on each end.
Complementary single-strand DNA oligonucleotides were purified by denaturing
polyacrylamide gel electrophoresis and annealed. Briefly, oligonucleotides (5-25 nmols
in 25 µl TE), formamide (25 µl), and bromophenol blue (1 µl of 1% solution) were
heated at 90° C for three minutes before being separated on an 18% polyacrylamide urea
gel (30 ml 29% acrylamide 1% bis-acrylamide, 31.5 urea, 7.5 10X TBE, 13.5 ml H2O,
0.5 ml 10% ammonium persulfate, 35 µl TEMED) for 2-3 hours at 400 volts. The gel was
stained in 5% ethidium bromide for 5 minutes with agitation. The oligonucleotides were
excised from the gel, and the excised slices were crushed and incubated in 5 ml of TE
overnight at 37° C with agitation. The solution was syringe filtered and concentrated by
sec-butanol extraction. The DNA was precipitated with 3 M NaCl (33 µl), 1 M MgCl2 (5
µl), and 1.3 ml ethanol at -80° C for 15 minutes and centrifuged for 15 minutes. The
DNA pellet was washed in 80% ethanol, dried, and resuspended in 30 µl TE. TNE (500
µl 1 M Tris pH 8, 100 µl 0.5 M EDTA, 1.67 ml 3M NaCl, up to 50 ml H2O) was added to
obtain 1 µg/µl single-stranded oligonucleotide concentration. Equal volumes of
complementary strands were combined, boiled for 10 minutes, and cooled to room
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temperature

to

allow

for

annealing.

Concentrations

were

determined

by

spectrophotometry.
In Vitro Transcription/Translation
SOX9 was generated by in vitro transcription/translation of a SOX9 expression
plasmid using the TNT Coupled Wheat Germ Extract System (Promega). Briefly, Wheat
Germ Extract (25 µl), reaction buffer (2 µl), T7 RNA polymerase (1 µl), amino acid
mixture (1 nmol), ribonuclease inhibitor (40 U), and SOX9 DNA template (1 µg) were
combined in a single tube and incubated at 30° C for 60-90 minutes. In negative control,
DNA template was omitted from the reaction. Control reactions were prepared as
described with the substitution of

35

S-methionine for methionine with either DNA

template for SOX9, control template, or no DNA template. Products from reactions
containing

35

S-methionine were separated by SDS-PAGE (10%) and visualized using

autoradiography in order to verify correct protein product size (Figure 1).
Electrophoretic Mobility Shift Assay (EMSA)
To determine whether SOX9 binds to the identified potential binding sites,
EMSAs were performed using each wild-type and mutant enhancer for Col9a1 D1/D2,
Col9a1 M1/M2/D1/D2, and Col9a1 E1/E2, and CRTL1 C1/C2 as DNA probes. To
prepare DNA probes for EMSAs, 5’ GATC overhangs of each double-stranded
oligonucleotide were

32

P radiolabeled by end filling. DNA Polymerase I Klenow

fragment (5 U), α32P-dGTP (500 uCi), dNTPs not including dGTP (250 nmol each), and
double-stranded enhancer probe (2 pmol) were incubated at 37° C for 30-45 minutes.
Probes were purified from unincorporated α32P-dGTP by Sephadex G-50 filtration using
nick-columns (Amersham Biosciences). Probe radioactivity was determined by
8

scintillation counting and different probes were diluted to the same specific activity with
non-radiolabeled probe.
DNA-protein binding reactions were performed with radiolabeled probes (2 µl)
and SOX9 (1 µl) generated by in vitro transcription/translation. Reactions were carried
out at room temperature for 45 minutes in a DNA binding buffer containing 20 mM
Hepes (pH 7.9), 10% glycerol, 50 mM KCl, 0.05% Nonidet NP-40, 0.5 mM EDTA, 0.5
mM DTT, and 1 mM PMSF. dGdC (0.5-2 µg ) was added as a non-specific competitor.
In negative controls, blank samples made in transcription/translation reaction were
substituted for SOX9. To supershift SOX9 in one lane of each duplicate, anti-SOX9
antibody (480 ng) was pre-incubated with SOX9 for 20-30 minutes before the addition of
probes. Samples were separated using a 4% polyacrylamide gel, dried to filter paper, and
visualized by autoradiography.
Plasmid Construction
4x Enhancer-Reporter Plasmids
Purified enhancers were used to construct plasmids containing four tandem copies
of an enhancer upstream of a minimal promoter and a luciferase reporter gene. Enhancers
(5 µg) were phosphorylated using T4 kinase (10 U), kinase 10x buffer (4 µl), ATP (4 µl
10 mM) in a 40 µl reaction incubated at 37° C for 30 minutes. Phenol chloroform
extraction and ethanol precipitation were then performed to purify the enhancers. The
double-stranded enhancers with sticky ends resembling ends digested with BamHI and
BglII were ligated upstream of the Col2a1 minimal promoter in previously digested and
dephosphorylated Bluescript vector containing an ampicillin resistance gene. Competent
cells were transformed with the ligated plasmid and plated on ampicillin agar plates. The

9

next day, transformed colonies were grown in LB broth (5 ml) containing ampicillin at
37° C with shaking for 12-16 hours. Plasmid DNA was extracted from overnight cultures
using the Miniprep plasmid prep kit (Qiagen). To multermerized the enhancer to four
copies in tandem, Bluescript plasmid containing one copy of the enhancer and the
minimal promoter was double digest with BamHI/HindIII and BglII/HindIII resulting in a
DNA segment containing the enhancer and the promoter and another segment containing
one copy of the enhancer and the vector without the promoter. The digestion products
were separated on a 1% agarose gel and bands of the correct size were excised from the
gel. Qiaex II DNA extraction (Qiagen) products were used to extract the DNA from the
gel. By ligating the two segments together using T4 ligase, a plasmid containing two
copies of the enhancer and the minimal promoter was formed. After transforming cells
with ligated DNA, plating cell, picking colonies and growing overnight cultures, and
performing plasmid prep on the overnight culture, another double digest was performed
on this plasmid. This produced a DNA segment that contained two copies of the enhancer
region and the minimal promoter and another segment that contained two copies of the
enhancer and the vector without the promoter. After separating the digested plasmid on a
gel, cutting out the appropriate bands, and extracting the DNA from the gel, these two
DNA segments were ligated together resulting in a plasmid that contained four copies of
the enhancer and the minimal promoter in the Bluescript vector. This new plasmid was
again used to transform cells, which were plated, colonies picked, cultures grown, and
plasmid preps performed on the cultures. This plasmid was then digested to remove the
four copies of the enhancer and the minimal promoter. After being separated on a gel,
excising the appropriate bands, and extracting the DNA from the gel, this segment was
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ligated into the luciferase reporter plasmid p95Luc immediately upstream of the reporter
plasmid. The plasmids were sequenced by the BYU DNA Sequencing Center to verify
correct construction.
Col9a1 M1/M2/D1/D2 Enhancer-Reporter Plasmid
To create the Col9a1 M1/M2/D1/D2 enhancer plasmid, PCR was used to amplify
the 96-basepair D enhancer region described by Bernard et al. (1), which was then ligated
into Bluescript vector containing the minimal promoter. The single copy of the enhancer
and promoter were then removed and ligated into the luciferase reporter plasmid. Briefly,
PCR was performed using primers complimentary to the ends of the enhancer region of
interest

(Forward

TTAAGGATCCAGTGGGCACATTTTTAC,

Reverse

GGCGAGATCTATC TGCTATAGGAGTAC). DNA template was extracted from
human white blood cells using the DNeasy Tissue Kit (Qiagen). PCR reaction contained
Platinum Taq DNA polymerase (1 U) (Invitrogen), 10x PCR buffer without MgCl2 (5 µl),
dNTP mix (10 nmols), MgCl2 (75 nmols), forward and reverse primers (5 pmols each),
DNA template (0.25-1.0 µg), and water (up to 50 µl). The reaction started at 94° C for 2
minutes followed by 35 cycles of PCR (94° C for 30 seconds, 55° C for 30 seconds, 72°
C for 30 seconds). PCR product was purified using the QIAquick PCR Purification kit
(Qiagen). The purified PCR product was then digested with BamHI/BglII (15 U each)
(Fisher) with 10x Buffer B at 37° C for 3.5 hours. Enzymes and salts were removed using
QIAquick PCR Purification kit (Qiagen). The PCR product was ligated into linear
Bluescript vector (20-50 ng) upstream of the Col2a1 minimal promoter with T4 Ligase
(12 U) (Fisher) and 10x Ligase Buffer (4 µl) at 16° C overnight. Competent cells were
transformed with the ligated plasmid, plated, colonies picked, and cultures grown.
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Plasmid DNA was extracted from overnight cultures using Miniprep plasmid prep kit
(Qiagen).
The M1/M2/D1/D2 enhancer and the promoter were removed from Bluescript
using HindIII and SpeI. Due to the presence of a HindIII cut site within the enhancer, the
plasmid was first digested with SpeI (70 U) for 4 hours followed by an incomplete
digestion with HindIII (5 U) for 10 minutes. The digest products were separated on a 2%
agarose gel and the segment containing the complete enhancer and promoter was
extracted from the gel and ligated into the luciferase reported plasmid, p95Luc. The
plasmid was sequenced by the BYU DNA Sequencing Center to verify correct
construction.
Mutagenesis
To prevent SOX9 binding, mutations were made to each of the four putative
SOX9 binding sites located within the Col9a1 M1/M2/D1/D2 enhancer –
M1*/M2/D1/D2, M1/M2*/D1/D2, M1/M2/D1*/D2, M1/M2/D1/D2*. Mutations to
Col9a1 M1/M2/D1/D2 in p95Luc were made using QuikChange II Site-Directed
Mutagenesis (Stratagene). Briefly, complementary primers which contained the
mutations were designed and purified as described in Enhancer Synthesis and
Purification.

Primers

were

M1*/M2/D1/D2

forward

AACCTCAGCCCTC

TGGCAGCTTCCACTGTATT, M1*/M2/D1/D2 reverse AATACAGAGGAAGCTGCC
AGAGGGCTGAGGTT, M1/M2*/D1/D2 forward TCTGAAAGCTTCCACCTGATTC
CTATAGCAGTT, M1/M2*/D1/D2 reverse AACTGCTATAGGAATCAGGTGGAA
GCTTTCAGA, M1/M2/D1*/D2 forward TGTATTCCTATAGCAGTTCTGGCAGCTG
CCATTGTACTCCTATA, M1/M2/D1*/D2 reverse TATAGGAGTACAATGGCAGCT
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GCCAGAACTGCTATAGGAATACA, M1/M2/D1/D2*-A forward AGCAGTTCTGA
AAGCTGCCGGCGTACTCCTATAGCAGATAGATC, M1/M2/D1/D2*-A reverse GA
TCTATCTGCTATAGGAGTACGCCGGCAGCTTTCAGAACTGCT, M1/M2/D1/D2*
forward

AGCAGTTCTGAAAGCTGCCGGCGTGCTCCTATAGCAGATAGATC,

M1/M2/D1/D2* reverse GATCTATCTGCTATAGGAGCACGCCGGCAGCTTTCAG
AACTGCT. These primers (125 ng each) were extended in a reaction containing 10x
reaction buffer (5 µl), M1/M2/D1/D2 plasmid template (20-50 ng), dNTP mix (1 µl),
PfuUltra HF DNA polymerase (2.5 U), and water (up to 50 µl). The reaction was started
at 95° C for 30 seconds and then 16-18 cycles were performed (95° C for 30 seconds, 55°
C for l minute, 68° C for 7 minutes) followed by 2 minutes at 4°C.
DpnI (10 U) was added to each amplification reaction to digest the parental
methylated template and incubated at 37° C for 1 hour. After incubating XL1-Blue
Supercompetent cells (50 µl) on ice for 30 minutes, the cells were transformed with the
digested product (1-2 µl) by heat shocking for 45 seconds at 42°C. The samples were
incubated on ice for 2 minutes before adding 0.5 ml NZY+ broth preheated to 42° C and
incubating for 1 hour at 37° C with shaking. The transformed cells were plated on LB
ampicillin plates and incubated at 37° C for 16 hours. Colonies were picked, overnight
cultures grown, and plasmid prep performed as previously described. The plasmids were
sequenced by the BYU DNA Sequencing Center to identify those containing the correct
mutations.
Due to the number and spacing of mutations required in M1/M2/D1/D2*, the
mutagenesis was performed in two steps. The M1/M2/D1/D2*-A primers introduced
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three mutations to the wild-type plasmid and the M1/M2/D1/D2* primer added the
fourth.
Tissue Culture
Rat chondrosarcoma (RCS) cells and 10T1/2 fibroblast cells were a gift from Dr.
Benoit de Crombrugghe of the University of Texas M.D. Anderson Cancer Center. Cells
were cultured at 37° C with 5% CO2 in supplemented Dulbecco’s modified Eagle
medium (D-MEM) (Gibco). Supplemented media contained 50 U/ml Penicillin (Cellgro),
50 µg/ml Streptomycin (Cellgro), 2 mM L-glutamine (Cellgro) and 10% fetal bovine
serum (HyClone).
Transient Transfection
RCS and 10T1/2 cells were transiently transfected in triplicate using enhancer
reporter plasmids, pSV-β-galactosidase expression plasmid as an internal control for
transfection efficiency, and empty p95Luc vector for negative control. Additionally,
SOX9 pcDNA3.1 expression vector was used in 10T1/2 transfections with empty
pcDNA3.1 vector as a negative control. Each transfection was repeated at least 3 times.
Lipofectamine Reagent (Invitrogen) was used to transfect the cells following
manufacturer’s instructions. Briefly, each 38.5 cm2 well was seeded with 2 x 105 cells
and incubated 18-24 hours with supplemented Dulbecco’s modified Eagle medium (see
Tissue Culture). The medium was removed and total plasmid DNA (2 µg) and 0.5%
Lipofectamine reagent in Opti-MEM (Gibco) (1 ml) were added to each well and
incubated 5-24 hours. One ml of 20% FBS in D-MEM was then added to produce a final
concentration of 10% FBS and cells were incubated 13-24 hours. This was followed by a

14

second incubation in fresh 10% FBS in D-MEM (with or without supplementary Lglutamine and antibiotics) for 18-24 hours.
Plus reagent (Invitrogen) was used to enhance transfection efficiency in RCS
transfections. Plasmids (2 µg) were diluted in D-MEM (100 µl) and then incubated with
Plus reagent (15-16 µl) for 15 minutes before adding 5% Lipofectamine reagent in DMEM (100 µl) and incubating 15 minutes. The solution was added to cells in 800 µl fresh
D-MEM and incubated for 3 hours. One ml of 20% FSB in D-MEM was added to
produce a final concentration of 10% FBS and cells were incubated 21 hours followed by
a second incubation in fresh complete media for 18-24 hours.
Cells were rinsed (3x) with cold PBS and placed on ice. Lysis solution (Tropix)
with 0.5 mM DTT was added to each well, cells were harvested by scraping, and cell
debris pelleted by 5 minute centrifugation at 14,000 rpm.
β-galactosidase production was measured using the Galacto-Light Plus system
(Tropix) according to manufacture’s instruction. Briefly, 100 µl Reaction Buffer
(substrate plus diluent) was added to cell extract (2 µl). After 30 minutes of incubation,
Accelerator (100 µl) was added to terminate the enzyme activity and trigger light
emission measured by the luminometer (TD-20/20 Turner Designs).
Luciferase production in transfected cells was measured using the Luciferase
Assay System (Promega). Luciferase assay reagent (100 µl) containing luciferin substrate
was added to cell extract (20 µl) and light produced from the luciferase reaction was
measured by the luminometer (TD-20/20 Turner Designs).
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Statistical Analysis
Analysis of variance (ANOVA) model was fit using transfection data to
determine the statistical significance between treatments. The basic model fit was
y=µ+αi+βj+(αβ)ij+εijk where µ is the overall mean of enhancer activity, αi is the effect of
SOX9 for the ith level, where ith levels are the presence or absence of SOX9, and βj is
the effect of the enhancer for the jth level, where the jth levels are p95Luc, wild-type, and
mutant enhancers. The interaction (αβ)ij is used to show whether the effects of the
presence or absence of SOX9 differs between enhancers. Random error is accounted for
with the term εijk. Effects were found to be significant using a confidence interval of 95%
(α = 0.05). We looked at the a) marginal mean of enhancer activity with each wild-type
and mutant as compared to p95Luc, b) marginal mean of enhancer activity in the
presence or absence of SOX9, and c) marginal mean of enhancer activity between two
enhancers with and without SOX9. Bonferroni post hoc tests were used to adjust for
multiple comparisons to obtain a family-wise error rate of 0.05.
Co-Immunoprecipitation
RCS cells were cultured in T75 culture flasks until 70-100% confluent. Cells were
lysed by incubation for 30 minutes with 1% NP-40 buffer (1.3-1.6 ml per 100 cm2 cell
culture) containing 150 mM NaCl, 50 mM Tris (pH 8) and protease inhibitors including
Leupeptin (1 µg/mg), Pepstatin (1 µg/ml), and PMSF (50 µg/ml). This and all subsequent
steps were carried out on ice or at 4°C. Lysed cells were harvested by scraping,
centrifuged at 10,000 rpm, and supernatant collected. Supernatant was incubated with
0.05-0.01 volumes of preimmune rabbit serum for one hour. To clear the lysate, A/G Plus
agarose beads (20 µl of 25% suspension) (Santa Cruz Biotechnology) were incubated
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with the lysate for 30-60 minutes with rotation, centrifuged at 2,500 rpm for 30 seconds
and then supernatant collected. The lysate clearing step was repeated one to three times.
A/G beads with crosslinked SOX9 antibody were added to cell lysate and incubated for 4
hours with rotation. The beads were pelleted by centrifuging at 2,500 rpm for one minute
and supernatant discarded. Beads were washed (2-4x) with 1 ml NP-40 buffer or PBS.
Pellet was resuspended in 40 µl Laemmli buffer with 5% β-mercaptoethanol, boiled for
3-5 minutes, and separated on a 10% polyacrylamide gel. The gel was rinsed for 30
minutes in water, stained overnight with SYPRO Ruby protein gel stain (Bio-Rad), and
destained for one hour in water. Unique bands were excised from the gel and stored at 20ºC.
A challenge with heavy background resulted from preimmune antibody added to
preclear nonspecific binding proteins from the cell lysate. Excess preimmune antibody
that was not removed form the cell lysate bound to A/G beads and because it was not
crosslinked to the beads it would be seen among the immunoprecipitated proteins
separated on the gel. To reduce this background, several incubations with A/G beads in
the cell lysate were performed to remove the preimmune antibody. The proteins bound
with each incubation were separated on a polyacrylamide gel so the level of background
could be determined.
Crosslinking
Special consideration needed to be taken due to the similar size of SOX9 protein
(56 kDa) and IgG heavy chain. Anti-SOX9 antibody was crosslinked to A/G beads to
eliminate heavy chain protein seen on the polyacrylamide gel after protein separation so
that the presence of SOX9 could be seen.
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Anti-SOX9 polyclonal antibody (Chemicon International) was crosslinked to A/G
agarose beads using dimethylpimelimidate (DMP) (Pierce Chemical). Briefly, A/G
agarose beads (500 µl of 25% suspension) were washed with PBST (PBS containing
0.1% Tween 20 detergent). Beads were resuspended in PBST and anti-SOX9 antibody
(100 µg) was added and incubated at 4° C with rotation overnight to allow for binding of
antibody to the A/G agarose beads. Beads with bound antibody were then washed (3x)
and resuspended in 0.2 M sodium borate buffer (pH 9). DMP crosslinker (100 mg) was
dissolved in 0.2 M sodium borate buffer and incubated with the beads at room
temperature for one hour to allow for the crosslinking reaction to occur. The beads were
washed (3x) with 0.2 M triethanolamine (pH 8) and incubated in 0.2 M triethanolamine
for two hours at room temperature with rotation. This was followed by three washes with
0.1 M glycine buffer (pH 2.5) and then three washes with PBS buffer. The crosslinked
beads were stored in PBS at 4°C.
Immunoblot
After protein samples were separated on a 10% SDS polyacrylamide gel, proteins
were transferred to Westran Clear Signal membrane (Schleicher and Schuell Bioscience)
at 4° C in buffer containing 0.025 M Tris, 0.19 M glycine, 0.025% SDS, and 20%
methanol.
After transfer, the blot was rinsed in TBS-T (50 mM Tris pH 8, 15 mM NaCl, and
0.05% Tween-20) and blocked with 5% non-fat dry milk (Biorad) for one hour at room
temperature with agitation. Following blocking, the blot was rinsed in TBS-T. AntiSOX9 antibody (0.48 mg/ml) was diluted 1:5000 in blocking solution and incubated with
blot for 2.5 hours at room temperature with agitation. The blot was then rinsed with TBS-
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T once for 15 minutes and then three times for 5 minutes, all with agitation. The blot was
then incubated in blocking buffer containing 1:5000 dilution of peroxidase-conjugated
goat anti-rabbit secondary antibody (0.8 mg/ml) for 1.5 hours with agitation. The blot
was rinsed again with TBS-T once for 15 minutes and then three times for 5 minutes, all
with agitation. ECL Western blotting detection reagents (Amersham Bioscience) were
using to visualize secondary antibody by chemiluminescent reaction. After adding
detection reagent to the blot, the blot was exposed to autoradiography film.
Tryptic Digestion
An in-gel tryptic digest was performed on gel slices to prepare proteins for
peptide analysis as previously reported (12). Briefly, acetonitrile solution (50%
acetonitrile and 50 mM ammonium bicarbonate) (1.5 ml) was added to the gel slice and
incubated 30 minutes with shaking. The solution was then aspirated and reduction buffer
(100 mM ammonium bicarbonate, 5 mM DTT) (150 µl) was added to the gel slice and
incubated at 60ºC for 30 minutes. The buffer was aspirated and alkylation buffer (100
mM ammonium bicarbonate, 20 mM iodoacetamide) (150 µl) was added to the gel slice
and incubated in the dark for 30 minutes. Following the incubation, the solution was
aspirated and 100 mM ammonium bicarbonate (1 ml) was added to the gel slice and
incubated for 30 minutes with shaking. The ammonium bicarbonate was aspirated and the
gel slice was sectioned to increase surface area before being incubated in acetonitrile
solution (500 µl) for 30 minutes with shaking. The solution was aspirated and the gel
pieces dried by vacuum centrifugation. Gel pieces were then hydrated in trypsin solution
(trypsin 20 ng/µl, 25mM ammonium bicarbonate) and excess solution was removed.
Ammonium bicarbonate was added until all gel pieces were submerged. After overnight
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incubation at 37ºC with motion, formic acid (88%) (1 µl) was added to the gel pieces
which were then sonicated for 20 minutes.
Mass Spectrophotometry
Protein samples were sent to the Brigham Young University Proteomics and
Biological Mass Spectrophotometry Facility or the Columbia University Protein Core
Facility for identification using oMALDI and MS/MS mass spectrophotometry.
Columbia’s facility performed tryptic digestion in house.
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RESULTS

Col9a1 D Enhancer
After the putative SOX9 binding site, D1, was identified adjacent to the known
site, D2, EMSAs were performed to determine whether SOX9 binds to D1 in vitro.
Probes used included wild-type, D1/D2, as well as mutants D1*/D2 and D1/D2* (Table
1A). The EMSAs showed that SOX9 binds as a dimer and a monomer to the wild-type
Col9a1 D1/D2 enhancer (Figure 2). Inclusions of anti-SOX9 antibody supershifted both
complexes confirming that they both contain SOX9. Mutations of the D1 site (D1*/D2)
allowed for monomeric but prevented dimeric SOX9 binding. Mutation of the D2 site
(D1/D2*) prevented both dimeric and monomeric binding, even though the D1 site was
still intact.
To determine whether the binding of SOX9 to Col9a1 D1/D2 and D1*/D2 in vitro
correlated with transcriptional activity in vivo, transient transfections were done in rat
chondrosarcoma cells (RCS) where SOX9 is readily expressed (Figure 3). To our
surprise, the presence of Col9a1 D1/D2 or D1*/D2 enhancers did not result in an increase
in transcriptional activity compared with the no-enhancer control, p95Luc. Although they
did not contain the full length enhancer previously identified by Bernard et al. (1), these
enhancers contained the same SOX9 binding site, D2, which had been identified as the
critical site for activation. We speculated that another critical sequence must exist in the
upstream region contained in Bernard’s enhancer but omitted from our D1/D2 enhancer.
To test this hypothesis, the same enhancer region as described by Bernard et al. (Table 1)
was used to construct a single-copy enhancer-reporter plasmid, which was tested in
transient transfections in RCS cells (Figure 4). The presence of this full enhancer region
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resulted in high activation as compared to the D1/D2 enhancer, indicating that the
upstream region does indeed contain critical elements. In searching for possible
transcription factor binding sites in this newly included upstream region, two new
putative SOX9 binding sites were identified (Table 1B). Substitution mutations were
made within these newly identified putative SOX9 binding regions, M1 and M2, so that
the importance of these sites could be assessed. The D1 and D2 sites were also mutated in
the context of this longer enhancer. Surprisingly, introducing a mutation to any one of the
four putative SOX9 binding sites within the M1/M2/D1/D2 enhancer resulted in a
complete elimination of activity (Figure 5), indicating that the two pairs do not work
independent from one another. Rather, these results suggest that the four binding sites
give rise to the formation of a SOX9 tetramer and that protein binding at all four sites is
required for enhancer activity.
To verify that the activity of the M1/M2/D1/D2 enhancer was a result of the
presence of SOX9, transient transfections were performed in 10T1/2 fibroblast cells.
Because SOX9 is not expressed in this cell line, comparisons were able to be made
between activity with the enhancer in the presence and absence of SOX9. Co-transfection
with a SOX9 expression plasmid increased the activity of the M1/M2/D1/D2 enhancer 6
fold (Figure 6A). Mutation of any one of the four SOX9 binding sites markedly
decreased enhancer responsiveness to SOX9, suggesting that SOX9 does, in fact, bind to
each of the four sites and that this binding is required for transcriptional activity (Figure
6B).
EMSAs were performed to confirm the ability of SOX9 to bind to the
M1/M2/D1/D2 enhancer and also to see whether SOX9 could bind when only one of the
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four SOX9 binding sites was mutated (Figure 7). From the supershifts resulting upon the
addition of anti-SOX9 antibody, we see that SOX9 is capable of binding to
M1/M2/D1/D2. All mutants except M1/M2/D1/D2* are also able to bind SOX9 to some
degree. Whether this is monomer, dimer, trimer, or tetramer SOX9, however, is not clear.
These results do suggest, however, that although SOX9 binding may still be possible if
one of the four sites is mutated, such binding does not promote transcriptional activation.
Col9a1 E Enhancer
EMSAs were performing using enhancers E1/E2, E1*/E2, and E1/E2* (Table 2A)
to determine whether SOX9 binds to the recently identified E1 site (Figure 8). Here again
we see both dimerized and monomeric SOX9 bound to the wild-type enhancer. When the
E1 site is mutated, SOX9 still binds as a monomer to the E2 site, but when the E2 site is
mutated, no SOX9 binding occurs.
To determine whether the SOX9 binding seen in vitro leads to activation in vivo,
RCS cells were transiently transfected with E1/E2, E1*/E2, and E1/E2* enhancer
reporter plasmids (Figure 9). Although E1/E2 did show some transcriptional activity,
activation was increased by less than 2 fold compared to the no-enhancer control,
p95Luc. In the E1*/E2 enhancer, this low level of transcriptional activation persisted,
suggesting that monomeric SOX9 was able to induce activation as much as the dimer in
this instance. The E1/E2* enhancer was much more transcriptionally active than
expected, considering that the EMSA showed no SOX9 bound to that enhancer. It is
likely that the introduction of the E2* mutation inadvertently created a new binding site
for a different transcriptional activator, making it impossible to detect the effect of the
loss of SOX9 binding.
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To determine whether transcriptional activation by these enhancers in RCS cells
was a result of SOX9 binding, transient transfections were performed in 10T1/2
fibroblast cells with and without the addition of SOX9 (Figure 10). Consistent with the
RCS transfection and EMSA results, the E1*/E2 mutant enhancer did remain partially
responsive to monomeric SOX9. The results observed with the E1/E2* enhancer,
however, were not expected. This enhancer was more strongly activated by SOX9 than
was the wild-type, even though no SOX9 bound this enhancer in EMSAs. It is possible
that the over-expression of SOX9 in 10T1/2 cells secondarily increased the expression of
another activating protein, which in turn bound and activated the mutant enhancer.
CRTL1 Enhancer
EMSAs were performing using enhancers C1/C2, C1*/C2, and C1/C2* (Table
2B) to determine whether SOX9 binds to the newly identified C2 site (Figure 11). Both
dimeric and monomeric SOX9 bound to the wild-type C1/C2 enhancer. Mutation of the
C2 site prevented dimeric but allowed monomeric SOX9 binding, but mutation of the C1
site eliminated all SOX9 binding.
To determine whether the SOX9 binding seen in vitro corresponds to
transcriptional activation in vivo, RCS cells were transiently transfected with C1/C2,
C1*/C2, and C1/C2* enhancer reporter plasmids (Figure 12). The wild-type C1/C2
enhancer was weak in RCS cells but did show statistically significant enhancer activity.
Mutation of either the C1 site (C1*/C2) or the C2 site (C1/C2*) abolished enhancer
activity, demonstrating that monomeric SOX9 binding cannot activate this enhancer.
Instead, dimeric SOX9 binding is required for activation by C1/C2 enhancer.
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Transient transfections of the C1/C2 enhancer-reporter plasmid were also
performed in 10T1/2 cells (Figure 13A). These experiments showed that in the presence
of SOX9, enhancer activity of C1/C2 is increased about 10 fold. Mutation of either the
C1 or C2 site reduces SOX9 responsiveness drastically (Figure 13B). Thus we confirm
that SOX9 is causing the increase in expression.
Co-Immunprecipitation
The presence of the dimerization domain in SOX9 allows for homodimer
formation but SOX9 is also thought to form heterodimers with a variety of other proteins.
Using co-immunoprecipitaion on RCS cells, we attempted to identify proteins that
hetrodimerize with SOX9, because these could be possible co-activators of importance in
transcription.
To verify the presence of SOX9 in the mix of extracted proteins
immunoprecipitated for the cell lysate, western blots were performed (Figure 14). These
blots showed SOX9 was affectively being immunoprecipitated from the cells. From the
co-immunoprecipitations, unique bands were identified compared to negative controls.
Unique bands were seen around 30 and 50 kDa and have been submitted for
identification by mass spectrometry.
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DISCUSSION

Dimeric SOX9
From the experiments performed, we have gained insight into how SOX9 binds
and regulates the enhancers for the Col9a1 and CRTL1 genes. Evidence is presented here
that within each pair of SOX9 binding sites, a primary and a secondary binding site exist.
EMSAs for Col9a1 D1/D2 and E1/E2, and CRTL1 C1/C2 all showed dimeric SOX9
binding to wild-type enhancer, monomeric SOX9 binding upon mutation of one site, and
no SOX9 binding upon mutation of the other site. When mutations were introduced to the
secondary SOX9 binding site of the pair, SOX9 was still able to bind to the other site as a
monomer. However, when the primary site in the pair was mutated, no SOX9 was able to
bind. The presence of primary and secondary SOX9 binding sites may indicate that the
formation of a SOX9 dimer occurs in a specific order for each pair. First, one monomer
of SOX9 binds to the primary site and once bound, the second SOX9 protein is able to
bind, allowing for dimer formation.
Binding of SOX9 to an enhancer in vitro, however, does not necessarily lead to
gene activation in vivo. Although monomeric SOX9 was able to bind and activate the
Col9a1 E1*/E2 enhancer in RCS cells, monomeric SOX9 also bound to enhancers
Col9a1 D1*/D2 and CRTL1 C1/C2* in EMSAs but no activation occurred in RCS cells.
SOX9 was also able to bind the Col9a1 M1/M2/D1/D2 mutants M1*/M2/D1/D2,
M1/M2*/D1/D2, and M1/M2/D1*/D2 in EMSAs. Even though SOX9 bound to these
mutant enhancers in EMSAs, they had no transcriptional activity in RCS cells.
Furthermore, we showed that the short D1/D2 enhancer bound dimeric SOX9 in EMSA
but had absolutely no enhancer activity in RCS cells.
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Interestingly, bound dimeric SOX9 results in completely different activation for
each enhancer considered in this study. For the Col9a1 M1/M2/D1/D2 enhancer, the
binding of dimeric SOX9 was not sufficient to induce activation. All four SOX9 binding
sites were required for activation to occur. The Col9a1 E1/E2 enhancer was only
activated slightly by dimeric SOX9, and the same level of activation occured upon
binding of monomeric SOX9. The CRTL1 C1/C2 enhancer was activated significantly by
dimeric SOX9 and not at all by monomeric SOX9.
Based upon the different activation levels with dimeric SOX9 bound to the
enhancers, it is quite possible that other proteins besides SOX9 are influencing the
regulation of one or more of these enhancers. Unique bands obtained from coimmunoprecipitation of SOX9 may contain proteins that alter the activity of SOX9. Upon
identification of these proteins, follow-up experiments would determine each protein’s
role as a co-regulator with SOX9.
Tetrameric SOX9
Upon first look at the arrangement of SOX9 binding sites in the Col9a1
M1/M2/D1/D2 enhancer, the hypothesis was made that SOX9 dimerization would occur
at each binding site pair and that binding of dimerized SOX9 at each pair would result in
some level of gene activation. We had anticipated when one of the SOX9 binding pairs
was mutated, an intermediate level of expression would occur. The fact that upon
mutation of any of the four sites no activation is seen indicates that the two pairs do not
work independent from one another. This implies that the four binding sites give rise to
the formation of a SOX9 tetramer or two interacting dimers. Thus, here we see a novel
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model for SOX9 binding where gene activation is dependent on the formation of a SOX9
tetramer instead of simply dimers.
The spacing between SOX9 binding sites within pairs has been shown to be
critical for function. We suggest that the spacing between the two pairs of SOX9 binding
sites within the Col9a1 M1/M2/D1/D2 enhancer may also be structurally critical to allow
for the formation and binding of a SOX9 tetramer. To determine the importance of this
spacing, follow-up experiments will test the activation of wild-type binding pairs with 4
base pairs added between the two pairs of sites.
Although the structure allowing for tetrametric SOX9 seems probable, the
possibility of other proteins making up part of the activating complex also exists. Without
defined bands each being shifted upon addition of anti-SOX9 antibody in EMSAs, it
remains uncertain exactly which proteins are included in the complex.
Despite the uncertainty about which proteins are a part of the activator, the
tetrameric complex apparently causes extraordinary strength of activation compared to
monomeric and dimeric SOX9 activation. Only 1x M1/M2/D1/D2 reporter plasmids were
used in transient transfections as opposed to 4x enhancer for the other reporter-plasmids,
which results in an unequal comparison of the strength of the enhancers. In order to make
a direct comparison between the strength of the activation for the Col9a1 enhancers,
M1/M2/D1/D2 and E1/E2, transient transfections need to be performed using a reporter
plasmid containing 4x M1/M2/D1/D2. Because a simple 1x copy M1/M2/D1/D2
reporter-plasmid activated the expression of the reporter gene ten-fold, whereas the 4x
copy of E1/E2 activated the reporter gene only two fold, it is likely that M1/M2/D1/D2 is
the predominant enhancer of Col9a1.
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In conclusion, the experiments performed in this study further elucidate the role
of SOX9 in the regulation of the Col9a1 and CRTL1 genes. Activation of the Col9a1
gene is largely due to tetrameric SOX9 binding at the M1/M2/D1/D2 enhancer and
minimally activated by dimeric or monomeric SOX9 binding at the E1/E2 enhancer.
Despite the weakness of the enhancer, dimeric SOX9 is necessary for the activation of
the CRTL1 C1/C2 enhancer. Through this study we validate the importance of not just
monomeric but of dimeric and perhaps tetrameric SOX9 as an activator of cartilage gene
expression.
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TABLES
A

B

Table 1 Col9a1 D wild-type and mutant enhancers contain putative SOX9 binding sites.
Previously identified SOX9 binding site (underlined in black) as well as putative SOX9 binding
sites are shown in red. Bases that are SOX9 binding consensus sequence mismatches are
underlined in red. SOX9 binding sites containing substitution mutations (shown in bold) have
names with asterisks. A) The 50-bp region containing the previously identified SOX9 binding
site, D2, and the putative SOX9 binding site, D1. B) The 96-bp region including D1 and D2 as
well as upstream putative SOX9 binding sites M1 and M2. The sequences bracketed by green
dashed lines were used in EMSAs.
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B

Table 2 Col9a1 E and CRTL1 wild-type and mutant enhancers contain putative SOX9
binding sites. Previously identified SOX9 binding site (underlined in black) as well as putative
SOX9 binding sites are shown in red. Bases that are SOX9 binding consensus sequence
mismatches are underlined in red. SOX9 binding sites containing substitution mutations (shown
in bold) have names with asterisks. A) Col9a1 E enhancer containing the previously identified
SOX9 binding site, E2, and the putative SOX9 binding site, E1. B) CRTL1 enhancer containing
the previously identified SOX9 binding site, C2, and the putative SOX9 binding site, C1.
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FIGURES

Figure 1 SOX9 made using in vitro transcription/translation is seen at 56 kDa (red arrow).
In the positive control lane, bands contain proteins from in vitro transcription/translation control
expression vector. In the negative control, no bands are seen.
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Figure 2 Dimeric and monomeric SOX9 bind to Col9a1 D1/D2 enhancer and monomeric
SOX9 binds to mutant D1*/D2. Electrophorectic Mobility Shift Assays were performed using
in vitro made SOX9 and wild-type or mutant enhancers. Dimeric SOX9 is seen in lane 1,
monomeric SOX9 is seen in lanes 1 and 3, and anti-SOX9 antibody induced supershifts are seen
in lanes 2 and 4.

33

Figure 3 The Col9a1 D1/D2 enhancers do not activate gene expression. Transient
transfections were performed in RCS cells using the wild-type (D1/D2) or mutant (D1*/D2,
D1/D2*) enhancers-reporter plasmids. The no-enhancer reporter plasmid, p95Luc, functioned as
the control. None of the enhancers induced statistically significant levels of activation compared
to the control.
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Figure 4 The Col9a1 M1/M2/D1/D2 enhancer activates gene expression whereas D1/D2 does
not. Transient transfections were performed in RCS cells using reporter plasmids containing the
short D1/D2 enhancer or longer M1/M2/D1/D2 enhancer. The no-enhancer reporter plasmid,
p95Luc, functioned as the control. Only M1/M2/D1/D2 induced statistically significant levels of
activation compared to the control.
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Figure 5 The Col9a1 M1/M2/D1/D2 enhancer is unable to activate gene expression when
any of the four binding sites are mutated. Transient transfections were performed in RCS cells
using reporter plasmids containing the wild-type enhancer (M1/M2/D1/D2) or mutant enhancers
(M1*/M2/D1/D2, M1/M2*/D1/D2, M1/M2/D1*/D2, M1/M2/D1/D2*. The no-enhancer reporter
plasmid, p95Luc, functioned as the control. None of the mutants resulted in statistically
significant levels of activation compared to the control.
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Figure 6 The Col9a1 M1/M2/D1/D2 enhancer activates gene expression in fibroblast cells
when SOX9 is present. Transient transfections were performed in 10T1/2 fibroblast cells. A)
Cells were co-transfected with SOX9 expression vector (red), or empty expression vector
(yellow). B) Activation differences for each enhancer with and without SOX9 are plotted. The
activation with M1/M2*/D1/D2, M1/M2/D1*/D2, and M1/M2/D1/D2* is not statistically
significant.
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Figure 7 SOX9 binds to Col9a1 M1/M2D1/D2 enhancer and mutants
M1*/M2/D2/D2, M1/M2*/D2/D2, and M1/M2/D2*/D2. Electrophorectic Mobility Shift
Assays were performed using in vitro made SOX9 and wild-type or mutant enhancers. AntiSOX9 antibody induced supershifts are seen in lanes 2, 4, 6 and 8.
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Figure 8 Dimeric and monomeric SOX9 bind to Col9a1 E1/E2 enhancer and monomeric
SOX9 binds to mutant E1*/E2. Electrophorectic Mobility Shift Assays were performed using
in vitro made SOX9 and wild-type or mutant enhancers. Dimeric SOX9 is seen in lane 1,
monomeric SOX9 is seen in lanes 1 and 3, and anti-SOX9 antibody induced supershifts are seen
in lanes 2 and 4.
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Figure 9 The Col9a1 enhancers E1/E2 and E1/E2* activate gene expression equally.
Transient transfections were performed in RCS cells using reporter plasmids containing wild-type
(E1/E2) or mutant (E1*/E2, E1/E2*) enhancers. The no-enhancer reporter plasmid, p95Luc,
functioned as the control. All enhancers induced statistically significant levels of activation
compared to the control. The difference in levels of activation induced by E1/E2 and by E1*/E2
were not statistically significant.
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Figure 10 All Col9a1 E1/E2 enhancers activate gene expression in fibroblast cells when
SOX9 is present. Transient transfections were performed in 10T1/2 fibroblast cells. A) Cells
were co-transfected with SOX9 expression vector (red), or empty expression vector (yellow). B)
Activation differences for each enhancer with and without SOX9 are plotted.
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Figure 11 Dimeric and monomeric SOX9 bind to CRTL1 C1/C2 enhancer and monomeric
SOX9 binds to mutant C1/C2*. Electrophorectic Mobility Shift Assays were performed using
in vitro made SOX9 and wild-type or mutant enhancers. Dimeric SOX9 is seen in lane 1,
monomeric SOX9 is seen in lanes 1 and 5, and anti-SOX9 antibody induced supershifts are seen
in lanes 2 and 6.
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Figure 12 The CRTL1 C1/C2 enhancer activates gene expression whereas mutant enhancers
do not. Transient transfections were performed in RCS cells using reporter plasmids containing
wild-type (C1/C2) or mutant (C1*/C2, C1/C2*) enhancers. The no-enhancer reporter plasmid,
p95Luc, functioned as the control. Only the wild-type enhancer induced statistically significant
levels of activation compared to the control.
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Figure 13 All CRTL1 C1/C2 enhancers activate gene expression in fibroblast cells when
SOX9 is present. Transient transfections were performed in 10T1/2 fibroblast cells. A) Cells
were co-transfected with SOX9 expression vector (red), or empty expression vector (yellow). B)
Activation differences for each enhancer with and without SOX9 are plotted.
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Figure 14 Western blot of immunoprecipitated proteins confirms the presence of SOX9. In
lane 1, no bands are seen which indicates the crosslinking procedure was successful. In lanes 2
and 4, bands show the presence of SOX9 (56 kDa) and antibody heavy-chain and light chain (50
kDa and 30kDa respectively). In lane 5, SOX9 is not present. In lanes 6 and 7, SOX9 is seen. In
lane 8, no strong bands are present.
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